Concord Biotech Share Price
634.40+20.40 (+3.32%)
-56.83% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
CONCORDBIONSE
Concord Biotech Share Price
634.40+20.40 (+3.32%)
-56.83% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 11% | 7% | -12% |
| - | 2% | 3% | -30% |
| - | - | 2% | -16% |
| 20% | 19% | 19% | 14% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
CONCORDBIO
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,801 | ₹425150 Cr | 38.77 | 8.29 | 58.23 | ₹11479 Cr |
| 9,986 | ₹266265 Cr | 91.03 | 34.04 | 128.41 | ₹2568 Cr |
| 4,674.2 | ₹176301 Cr | 83 | 14.04 | 106.21 | ₹2163 Cr |
| 2,331.7 | ₹125352 Cr | 93.56 | 8.17 | 33.94 | ₹889 Cr |
| 1,260 | ₹123591 Cr | 27.39 | 9.42 | 62.53 | ₹5040 Cr |
| 1,366.7 | ₹114351 Cr | 40.84 | 11.08 | 59.2 | ₹4196 Cr |
| 1,395.3 | ₹112474 Cr | 38.82 | 10.86 | 52.6 | ₹3879 Cr |
| 2,498 | ₹102315 Cr | 45.62 | 17.23 | 76.26 | ₹1913 Cr |
| 1,702.6 | ₹97757 Cr | 26.33 | 17.95 | 96.84 | ₹3505 Cr |
| 2,035.3 | ₹92007 Cr | 16.64 | 30.95 | 154.35 | ₹5333 Cr |
| 634.4 | ₹12866 Cr | 45.55 | 6.75 | 34.15 | ₹261 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹309 Cr | ₹257 Cr | ₹326 Cr | ₹278 Cr | ₹247 Cr | ₹204 Cr | ₹430 Cr | ₹244 Cr | ₹310 Cr | ₹216 Cr | ₹319 Cr | ₹241 Cr | ₹262 Cr | ₹195 Cr | ₹273 Cr | ₹241 Cr | ₹159 Cr | ₹181 Cr |
| ₹10 Cr | ₹13 Cr | ₹15 Cr | ₹10 Cr | ₹13 Cr | ₹14 Cr | ₹9 Cr | ₹15 Cr | ₹10 Cr | ₹10 Cr | ₹11 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹12 Cr | ₹9 Cr | ₹6 Cr | ₹8 Cr |
| ₹319 Cr | ₹270 Cr | ₹341 Cr | ₹288 Cr | ₹260 Cr | ₹218 Cr | ₹439 Cr | ₹259 Cr | ₹320 Cr | ₹226 Cr | ₹330 Cr | ₹249 Cr | ₹270 Cr | ₹201 Cr | ₹285 Cr | ₹250 Cr | ₹165 Cr | ₹189 Cr |
| ₹223 Cr | ₹193 Cr | ₹227 Cr | ₹198 Cr | ₹177 Cr | ₹160 Cr | ₹254 Cr | ₹160 Cr | ₹187 Cr | ₹148 Cr | ₹198 Cr | ₹148 Cr | ₹156 Cr | ₹136 Cr | ₹158 Cr | ₹143 Cr | ₹133 Cr | ₹130 Cr |
| ₹115 Cr | ₹95 Cr | ₹134 Cr | ₹109 Cr | ₹102 Cr | ₹75 Cr | ₹200 Cr | ₹113 Cr | ₹147 Cr | ₹92 Cr | ₹145 Cr | ₹114 Cr | ₹127 Cr | ₹79 Cr | ₹141 Cr | ₹121 Cr | ₹44 Cr | ₹72 Cr |
| ₹3 L | ₹4 L | ₹8 L | ₹8 L | ₹6 L | ₹6 L | ₹10 L | ₹10 L | ₹10 L | ₹24 L | ₹46 L | ₹50 L | ₹84 L | ₹75 L | ₹1 Cr | ₹91 L | ₹1 Cr | ₹1 Cr |
| ₹96 Cr | ₹77 Cr | ₹114 Cr | ₹87 Cr | ₹83 Cr | ₹57 Cr | ₹185 Cr | ₹99 Cr | ₹133 Cr | ₹78 Cr | ₹131 Cr | ₹100 Cr | ₹113 Cr | ₹65 Cr | ₹126 Cr | ₹106 Cr | ₹30 Cr | ₹58 Cr |
| ₹70 Cr | ₹56 Cr | ₹89 Cr | ₹64 Cr | ₹61 Cr | ₹43 Cr | ₹142 Cr | ₹74 Cr | ₹99 Cr | ₹58 Cr | ₹97 Cr | ₹75 Cr | ₹84 Cr | ₹48 Cr | ₹94 Cr | ₹79 Cr | ₹22 Cr | ₹43 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — |
| ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr |
| ₹2007 Cr | ₹1802 Cr | ₹1516 Cr | ₹1280 Cr | ₹1094 Cr | ₹990 Cr | ₹761 Cr |
| ₹2007 Cr | ₹1802 Cr | ₹1516 Cr | ₹1280 Cr | ₹1094 Cr | ₹990 Cr | ₹761 Cr |
| ₹2017 Cr | ₹1813 Cr | ₹1527 Cr | ₹1290 Cr | ₹1103 Cr | ₹999 Cr | ₹770 Cr |
| -₹2 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹6 Cr | ₹31 Cr | ₹56 Cr | ₹36 Cr |
| ₹42 Cr | ₹34 Cr | ₹28 Cr | ₹23 Cr | ₹21 Cr | ₹17 Cr | ₹15 Cr |
| ₹1 Cr | ₹63 L | ₹2 Cr | ₹16 L | ₹31 L | ₹2 Cr | ₹3 Cr |
| ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| ₹48 Cr | ₹37 Cr | ₹32 Cr | ₹32 Cr | ₹54 Cr | ₹77 Cr | ₹55 Cr |
| — | — | — | — | — | — | — |
| ₹102 Cr | ₹113 Cr | ₹94 Cr | ₹94 Cr | ₹83 Cr | ₹46 Cr | ₹71 Cr |
| ₹56 Cr | ₹55 Cr | ₹38 Cr | ₹62 Cr | ₹66 Cr | ₹54 Cr | ₹42 Cr |
| ₹0 | ₹38 L | ₹0 | ₹0 | ₹4 Cr | ₹5 Cr | ₹0 |
| ₹11 Cr | ₹16 Cr | ₹9 Cr | ₹36 Cr | ₹191 Cr | ₹131 Cr | ₹110 Cr |
| ₹169 Cr | ₹184 Cr | ₹142 Cr | ₹192 Cr | ₹344 Cr | ₹236 Cr | ₹223 Cr |
| ₹2232 Cr | ₹2034 Cr | ₹1701 Cr | ₹1514 Cr | ₹1502 Cr | ₹1313 Cr | ₹1049 Cr |
| ₹4 Cr | ₹4 Cr | ₹14 Cr | ₹14 Cr | ₹13 Cr | ₹4 Cr | ₹4 Cr |
| ₹0 | ₹38 L | ₹6 Cr | ₹31 Cr | ₹61 Cr | ₹86 Cr | ₹48 Cr |
| — | — | — | — | — | — | — |
| ₹1163 Cr | ₹1097 Cr | ₹828 Cr | ₹793 Cr | ₹720 Cr | ₹645 Cr | ₹311 Cr |
| ₹374 Cr | ₹302 Cr | ₹253 Cr | ₹200 Cr | ₹147 Cr | ₹99 Cr | ₹72 Cr |
| ₹789 Cr | ₹795 Cr | ₹575 Cr | ₹593 Cr | ₹573 Cr | ₹546 Cr | ₹240 Cr |
| ₹78 Cr | ₹50 Cr | ₹211 Cr | ₹173 Cr | ₹74 Cr | ₹18 Cr | ₹141 Cr |
| ₹89 Cr | ₹19 Cr | ₹2 Cr | ₹12 L | ₹26 L | ₹37 L | ₹81 L |
| ₹89 Cr | ₹19 Cr | ₹2 Cr | ₹12 L | ₹26 L | ₹37 L | ₹81 L |
| ₹18 Cr | ₹12 Cr | ₹13 Cr | ₹12 Cr | ₹221 Cr | ₹141 Cr | ₹128 Cr |
| ₹7 Cr | ₹23 Cr | ₹3 Cr | ₹9 Cr | ₹82 L | ₹45 L | ₹67 L |
| ₹982 Cr | ₹899 Cr | ₹804 Cr | ₹786 Cr | ₹869 Cr | ₹706 Cr | ₹510 Cr |
| — | — | — | — | — | — | — |
| ₹402 Cr | ₹317 Cr | ₹244 Cr | ₹137 Cr | ₹73 Cr | ₹141 Cr | ₹198 Cr |
| ₹326 Cr | ₹240 Cr | ₹208 Cr | ₹212 Cr | ₹195 Cr | ₹154 Cr | ₹111 Cr |
| ₹460 Cr | ₹522 Cr | ₹350 Cr | ₹274 Cr | ₹232 Cr | ₹178 Cr | ₹184 Cr |
| ₹14 Cr | ₹1 Cr | ₹47 Cr | ₹43 Cr | ₹89 Cr | ₹61 Cr | ₹3 Cr |
| ₹18 Cr | ₹29 Cr | ₹27 Cr | ₹46 Cr | ₹33 Cr | ₹40 Cr | ₹14 Cr |
| ₹30 Cr | ₹27 Cr | ₹21 Cr | ₹16 Cr | ₹10 Cr | ₹34 Cr | ₹29 Cr |
| ₹1250 Cr | ₹1135 Cr | ₹896 Cr | ₹728 Cr | ₹633 Cr | ₹607 Cr | ₹539 Cr |
| ₹1081 Cr | ₹951 Cr | ₹754 Cr | ₹536 Cr | ₹288 Cr | ₹371 Cr | ₹315 Cr |
| ₹2232 Cr | ₹2034 Cr | ₹1701 Cr | ₹1514 Cr | ₹1502 Cr | ₹1313 Cr | ₹1049 Cr |
| ₹193 | ₹173 | ₹146 | ₹123 | ₹1,160 | ₹1,051 | ₹810 |
| ₹193 | ₹173 | ₹146 | ₹123 | ₹105 | ₹96 | ₹74 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| ₹345 Cr | ₹495 Cr | ₹413 Cr | ₹322 Cr | ₹238 Cr | ₹313 Cr | ₹213 Cr |
| ₹37 Cr | ₹30 Cr | ₹37 Cr | ₹47 Cr | ₹53 Cr | ₹18 Cr | ₹12 Cr |
| -₹14 Cr | -₹171 Cr | -₹81 Cr | -₹52 Cr | -₹22 Cr | -₹89 Cr | -₹22 Cr |
| ₹367 Cr | ₹354 Cr | ₹369 Cr | ₹316 Cr | ₹268 Cr | ₹242 Cr | ₹204 Cr |
| ₹267 Cr | ₹245 Cr | ₹265 Cr | ₹246 Cr | ₹207 Cr | ₹167 Cr | ₹155 Cr |
| -₹143 Cr | -₹160 Cr | -₹155 Cr | -₹158 Cr | -₹112 Cr | -₹195 Cr | -₹113 Cr |
| -₹113 Cr | -₹99 Cr | -₹99 Cr | -₹85 Cr | -₹100 Cr | ₹31 Cr | -₹43 Cr |
| ₹11 Cr | -₹14 Cr | ₹12 Cr | ₹3 Cr | -₹4 Cr | ₹3 Cr | -₹1 Cr |
| ₹90 L | ₹15 Cr | ₹3 Cr | ₹67 L | ₹5 Cr | ₹2 Cr | ₹4 Cr |
| ₹12 Cr | ₹90 L | ₹15 Cr | ₹3 Cr | ₹67 L | ₹5 Cr | ₹2 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found
Concord Biotech Share Price
634.40+20.40 (+3.32%)
-56.83% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 1
Bearish signals: 4 out of 9 oscillators
RSI
45.40Neutral
STOCH %K
47.22Neutral
MACD Level(12,26)
-23.58Sell
Ultimate Oscillator
44.50Sell
Aroon Oscillator
-56.00Sell
BOP
0.61Buy
CCI
-71.95Neutral
Williams %R
-52.78Neutral
Momentum
-56.65Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 6 out of 9 moving averages
EMA 9
628.11Buy
SMA 9
628.93Buy
EMA 21
650.02Sell
SMA 21
651.58Sell
EMA 50
675.60Sell
SMA 50
699.30Sell
EMA 200
678.54Sell
SMA 200
633.03Buy
WMA 20
637.36Sell
Pivot
Pivot
Classic
Resistance 5
769.15
Resistance 4
728.65
Resistance 3
688.15
Resistance 2
647.65
Resistance 1
630.80
Pivot
607.15
Support 1
590.30
Support 2
566.65
Support 3
526.15
Support 4
485.65
Support 5
445.15
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Concord Biotech Share Price
634.40+20.40 (+3.32%)
-56.83% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 44.09% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| 7.28% | 7.53% | 7.79% | 7.58% | 8.03% | 9.10% |
| 5.11% | 4.97% | 4.92% | 5.13% | 5.01% | 4.16% |
| 5.84% | 4.40% | 4.30% | 4.44% | 4.53% | 4.68% |
| 37.68% | 39.02% | 38.91% | 38.77% | 38.35% | 37.98% |
Bulk & block deals
Name
Dsp Mutual Fund
1575773 Ontario Inc
Nk Securities Research Private Limited
Nk Securities Research Private Limited
The Vanguard Group Inc A/C Vanguard Emerging Markets Stock Index Fund A Series Of Vanguard Internat
The Vanguard Group Inc A/C Vanguard Total International Stock Index Fund
Ubs Principal Capital Asia Limited
Norges Bank On Account Of The Government Pension Fund Global
1575773 Ontario Inc
Societe Generale
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 31 Aug 2026 | Purchase | 180.86 Cr | ₹1,404.10 | 12.88 L | Bulk | 1.231276 | BSE |
| 31 Aug 2026 | Sell | 293.78 Cr | ₹1,404.10 | 20.92 L | Bulk | 2.000001 | BSE |
| 25 Feb 2026 | Purchase | 75.14 Cr | ₹1,217.94 | 6.17 L | Bulk | 0.589729 | NSE |
| 25 Feb 2026 | Sell | 75.18 Cr | ₹1,218.58 | 6.17 L | Bulk | 0.589729 | NSE |
| 20 Sep 2024 | Purchase | 149.84 Cr | ₹2,596.08 | 5.77 L | Bulk | 0.551715 | NSE |
| 20 Sep 2024 | Purchase | 181.19 Cr | ₹2,596.08 | 6.98 L | Bulk | 0.66714 | NSE |
| 20 Sep 2024 | Sell | 191.69 Cr | ₹2,589.86 | 7.40 L | Bulk | 0.707499 | NSE |
| 28 May 2024 | Purchase | 83.22 Cr | ₹1,386.95 | 6 L | Bulk | 0.573525 | NSE |
| 28 May 2024 | Sell | 483 Cr | ₹1,361.26 | 35.48 L | Bulk | 3.391646 | NSE |
| 25 Jan 2024 | Purchase | 21.81 Cr | ₹1,421.70 | 1.53 L | Block | 0.146651 | BSE |
Insider trading & SAST
Client name
Chandrashekhar Mukundrao Chawan
Prakash Lalchand Sajnani
Devang Bhatt
Kanishka Kapoor
Ravi Kapoor
1575773 Ontario Inc
Rajendra Modi
Raksha Modi
Mr. Chandrashekhar Mukundrao Chawan
Raksha Modi
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23 Sep 2024 | Designated Person | Disposal | 0.000956 | 0.01 | 21.09 L | ₹2,109.40 | 1 K | 16 Sep 2024 - 22 Sep 2024 | Market Sale | 9,039 | Insider Trading | — | Equity Shares |
| 23 Sep 2024 | Designated Person | Disposal | 0.004779 | 0.02 | 1.08 Cr | ₹2,168.80 | 5 K | 16 Sep 2024 - 22 Sep 2024 | Market Sale | 17,000 | Insider Trading | — | Equity Shares |
| 04 Sep 2024 | Designated Person | Disposal | 0.002868 | 0.01 | 52.04 L | ₹1,734.79 | 3 K | 02 Sep 2024 | Market Sale | 8,056 | Insider Trading | — | Equity Shares |
| 13 Jun 2024 | Directors Immediate Relative | Disposal | 0.009559 | 0 | 0 | — | 10 K | 12 Jun 2024 | Market Sale | 0 | Insider Trading | — | Equity Shares |
| 05 Jun 2024 | Director | Disposal | 0.009559 | 0.2 | 0 | — | 10 K | 04 Jun 2024 | Gift | 2,10,000 | Insider Trading | — | Equity Shares |
| 03 Jun 2024 | Other | Disposal | 3.39 | 2 | 0 | — | 35.48 L | 28 May 2024 | Market | 20,92,325 | SAST | 29(2) | — |
| 27 Feb 2024 | Designated Person | Disposal | 0.003823 | 0.02 | 59.98 L | ₹1,499.52 | 4 K | 26 Feb 2024 | Market Sale | 18,000 | Insider Trading | — | Equity Shares |
| 27 Feb 2024 | Employees Immediate Relative | Disposal | 0.001912 | 0.02 | 29.85 L | ₹1,492.37 | 2 K | 26 Feb 2024 | Market Sale | 18,000 | Insider Trading | — | Equity Shares |
| 24 Feb 2024 | Designated Person | Disposal | 0.000956 | 0.01 | 14.45 L | ₹1,444.90 | 1 K | 23 Feb 2024 | Market Sale | 10,039 | Insider Trading | — | Equity Shares |
| 24 Feb 2024 | Employees Immediate Relative | Disposal | 0.001912 | 0.02 | 29.33 L | ₹1,466.52 | 2 K | 23 Feb 2024 | Market Sale | 20,000 | Insider Trading | — | Equity Shares |
Concord Biotech Share Price
634.40+20.40 (+3.32%)
-56.83% past 1 Year
Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology, supplying too many countries including
Corporate Actions
Date
Type
Details
Company details
Concord Biotech Share Price
634.40+20.40 (+3.32%)
-56.83% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Concord Biotech Share Price
634.40+20.40 (+3.32%)
-56.83% past 1 Year
News
Concord Biotech Reports Higher Q2 EBITDA Despite Margin Contraction
Equity
CONCORDBIO
Concord Biotech Reports Stronger Second Quarter Net Profit Growth
Equity
CONCORDBIO
Concord Biotech Reports Strong Second Quarter Revenue Growth
Equity
CONCORDBIO
Concord Biotech Approves One To One Bonus Issue And Raises Capital
Equity
CONCORDBIO
Concord Biotech Q1 EBITDA rises sharply with improved margin performance
Equity
CONCORDBIO
Concord Biotech posts strong Q1 revenue growth on robust year-on-year performance
Equity
CONCORDBIO
Concord Biotech reports higher Q1 net profit on steady quarterly earnings
Equity
CONCORDBIO
Concord Biotech schedules Q1 FY2026 earnings conference call for investors
Equity
CONCORDBIO
Concord Biotech clears Kenya, Uganda inspections at Unit-II formulation plant
Equity
CONCORDBIO
Brazilian Health Regulatory Agency completes inspection at Concord Biotech’s API manufacturing facility in Limbasi
Equity
CONCORDBIO
Concord Biotech completes Anvisa inspection at Limbasi API site
Equity
CONCORDBIO
Concord Biotech zooms after getting USFDA’s nod for Tofacitinib Tablets
Equity
CONCORDBIO
Concord Biotech gets USFDA’s nod for Tofacitinib Tablets
Equity
CONCORDBIO
Concord Biotech gains USFDA nod for Tofacitinib tablets with US sales potential
Equity
CONCORDBIO
Concord Biotech soars on getting USFDA nod for Mycophenolate Mofetil for Oral Suspension
Equity
CONCORDBIO
Concord Biotech gets USFDA nod for Mycophenolate Mofetil oral suspension
Equity
CONCORDBIO
Kotak maintains Add rating on Concord Biotech with strong FY27–29 growth view
Equity
CONCORDBIO
Jefferies keeps Hold rating on Concord Biotech after weak Q4 print
Equity
CONCORDBIO
Concord Biotech informs about press release
Equity
CONCORDBIO
Concord Biotech upbeat on FY27 growth outlook from products, customers mix shift
Equity
CONCORDBIO